Twitter YouTube LinkedIn Reddit

Diagnos Inc.

Disclaimer: All stock information on InvestorIntel.com is currently being fed from multiple sources and is updated automatically every 10-minutes. The information on this site is for information purposes only and InvestorIntel Corp. is neither responsible nor liable for the accuracy of this data.

InvestorIntel Features on Diagnos Inc.

Expanding globally in the AI image based diagnosis sector, Diagnos is actively commercializing their CARA technology

CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely […]

Thompson on DIAGNOS and the ‘exploding’ AI healthtech industry

AI Healthcare Provider Diagnos Continues to Sign Deals and Partnerships Amid COVID-19 Crisis Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF […]

Diagnos’ Andre Larente on the benefits of using AI for the early detection of critical health issues

“Our (AI) technology works, its in production (CARA). We are fully funded….the markets we are going after are extremely big…” […]

Company Overview

Team | Website

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

News Releases

View All News

Twitter YouTube LinkedIn Reddit